Evaluation of the Efficacy and Safety of Anisoylated Plasminogen Streptokinase Activator Complex in Early Myocardial Infarction
In the 15 patients receiving a 20U dose of APSAC administered intravenously, recanalisation was effected in 11 (73%). These results compare favourably with those reported for intravenous tissue plasminogen activator and intracoronary streptokinase. Use of APSAC in this dose was associated with the development of a systemic lytic state in 12 of the 15 patients studied. Apart from a hypotensive reaction in 3 patients, no major adverse reactions attributable to APSAC were observed. Therefore, APSAC in a dose of 20U administered intravenously is safe and effective in the management of patients with early myocardial infarction. Successful coronary thrombolysis was always associated with the development of a systemic lytic state. This did not result in significant haemorrhagic complications in this small number of patients.
KeywordsStreptokinase Angiographic Evidence Anisoylated Plasminogen Streptokinase Activator Complex Anterior Infarction Intracoronary Streptokinase
Unable to display preview. Download preview PDF.